Tuoxin Pharmaceutical Group Co

Tuoxin Pharmaceutical Group Co EBIT Margin

The EBIT Margin (Operating Margin) of Tuoxin Pharmaceutical Group Co (301089.SZ) as of Nov 22, 2026 is -12.59 %. In the previous year, EBIT Margin (Operating Margin) was -3.30 % — a change of 281.79% (lower).

EBIT Margin

-12.59 %

YoY

281.79%

Last updated:

EBIT Margin (Operating Margin) of Tuoxin Pharmaceutical Group Co is 2025 -12.59 % . EBIT Margin (Operating Margin) of Tuoxin Pharmaceutical Group Co was 2024 -3.30 % . It decreases by 281.79% lower compared to the previous year.

Tuoxin Pharmaceutical Group Co's operating (EBIT) margin stands at -12.6%, down from 18.0% several years earlier.

The Tuoxin Pharmaceutical Group Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
22.13 CNY
Jan 1, 2019
21.39 CNY
Jan 1, 2020
28.59 CNY
Jan 1, 2021
18.01 CNY
Jan 1, 2022
41.43 CNY
Jan 1, 2023
39.07 CNY
Jan 1, 2024
-3.30 CNY
Jan 1, 2025
-12.59 CNY
The Tuoxin Pharmaceutical Group Co EBIT Margin history
YEAREBIT MarginYoY
-12.59 %+281.79%
-3.30 %-108.44%
39.07 %-5.69%
41.43 %+130.10%
18.01 %-37.03%
28.59 %+33.70%
21.39 %-3.36%
22.13 %+28,786.48%
0.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tuoxin Pharmaceutical Group Co Stock analysis

What does Tuoxin Pharmaceutical Group Co do? Tuoxin Pharmaceutical Group Co Ltd develops and sells chemical synthetic biological fermented nucleoside APIs and pharmaceutical intermediates. The company's main products include pyrimidine series, purine series, nucleotide series, nucleoside series, and other nucleoside (acid) products such as citicoline sodium, ribavirin, inosine, acyclovir, azvudine, cytosine, 5-fluorocytosine, cytidine, and uridine. These products serve the virus, anti-tumor, and nervous system drug markets. Tuoxin primarily sells its products domestically and internationally, targeting pharmaceutical companies that manufacture antiviral, anticancer, and neurological medications. The firm's revenue comes from the sale of these raw materials and intermediates to both domestic and overseas pharmaceutical manufacturers. The company focuses on nucleoside (acid) products for pharmaceutical applications, with key offerings like citicoline sodium and ribavirin used in antiviral treatments. Its product portfolio includes acyclovir for viral infections and azvudine for HIV treatment, alongside intermediates such as cytosine and uridine. Tuoxin's sales are directed toward pharmaceutical manufacturers in China and abroad, who incorporate these materials into their drug production processes. The firm's business model relies on supplying essential raw materials to the global pharmaceutical industry for the production of antiviral, anticancer, and neurological drugs. Tuoxin Pharmaceutical Group's revenue streams are derived from the production and sale of nucleoside-based APIs and intermediates. The company's primary customers are pharmaceutical manufacturers that require these materials for developing virus, anti-tumor, and nervous system drugs. The products are distributed across domestic and international markets, with the firm maintaining a focus on chemical synthetic biological fermented nucleoside products. The business model emphasizes direct sales of raw materials and intermediates to manufacturers rather than consumer-facing products. Tuoxin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tuoxin Pharmaceutical Group Co stock

EBIT Margin (Operating Margin) of Tuoxin Pharmaceutical Group Co is -12.59 % in 2025.

EBIT Margin (Operating Margin) of Tuoxin Pharmaceutical Group Co changed from -3.30 % to -12.59 %, representing a 281.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Tuoxin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Tuoxin Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Tuoxin Pharmaceutical Group Co

All Key Metrics — Tuoxin Pharmaceutical Group Co